To date its use has been investigated in several other tumor types including glioblastoma, [32] ovarian cancer [33], HER2 negative and CD44-positive triple negative breast cancer [34–36], and head and neck cancer [37]. This evidence concerns the gene ERBB2 and ovarian carcinoma.